2024 - Advanced AAV Processing and Potency through Characterisation of Capsid and Payload Heterogeneity

Enhancing adeno-associated virus (AAV) viral vector quality can significantly impact product efficacy and is essential to ensure patient safety. We invite you to join our team of experts for a deep dive into our AAV viral vector development expertise and showcase our recent breakthroughs.
In this webinar, our speakers will delve into how the characterisation of the contents and surface of AAV capsids has helped identify factors influencing charge heterogeneity, and, consequently, the potency of AAV products:
We will first present how VP1 deamidation, which has been associated with a decrease in potency, is also connected to hydrophobicity
We will investigate how production time within the bioreactor and AAV location inside or outside the cell affects capsid post-translational modifications and surface charge
We will finally demonstrate the importance of reducing and controlling the level of intermediate (partially full) and empty capsids, which can impact product efficacy and have potential implications for patient safety
After the webinar, we will host a live Q&A session, providing attendees with the opportunity to ask questions directly to the presenters. We look forward to your participation.
Keywords: Drug Development, CRO, Bioprocess Development, AAV, Viral Vector, Viral Vector Manufacturing, Cell & Gene Therapies, AAV Manufacturing, CDMO/CMO, Basic Research, AAV Capsid